*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals announced a shelf offering of $10 million today. This created an excellent buying opportunity which we used as our first entry. My team will be using the rest of September to build our position. We are expecting a bullish run before the end of the year, but if one happens sooner, we will of course act in our favor and do what we think is best.
Entry: $22.80
Take Profit: Somewhere above $32
If you want to see more, please like and follow us SimplyShowMeTheMoney
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Mirum Pharmaceuticals announced a shelf offering of $10 million today. This created an excellent buying opportunity which we used as our first entry. My team will be using the rest of September to build our position. We are expecting a bullish run before the end of the year, but if one happens sooner, we will of course act in our favor and do what we think is best.
Entry: $22.80
Take Profit: Somewhere above $32
If you want to see more, please like and follow us SimplyShowMeTheMoney
Nota
2nd Entry: $22.30Nota
3rd entry at $18.75!Nota
Holding. We're prepared for a retrace back to $18.75Trade fechado: objetivo atingido
We are currently up 8% on 
MIRM and holding 3 positions. We are exiting today because we believe that the stock market will head lower soon. We will be back!
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.
Aviso legal
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.